Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02955069
Recruitment Status : Active, not recruiting
First Posted : November 4, 2016
Last Update Posted : April 22, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This is a study to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) that have progressed on prior treatment.

Condition or disease Intervention/treatment Phase
Well-differentiated Non-functional NET of Thoracic Origin Well-differentiated Non-functional NET of Gastrointestinal Origin Well-differentiated Non-functional NET of Pancreatic Origin Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma Drug: PDR001 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Actual Study Start Date : February 14, 2017
Actual Primary Completion Date : August 10, 2018
Estimated Study Completion Date : April 3, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PDR001
110 patients will be administered PDR001 infusion.
Drug: PDR001
PDR001 is a high-affinity, ligand-blocking, humanized IgG4 antibody directed against Programmed Death-1 (PD-1) receptor that blocks the binding of PD-L1 and PD-L2. PDR001 dose is 400 mg infusion every 4 weeks.




Primary Outcome Measures :
  1. Overall response rate [ Time Frame: 1 year after last patient first treatment ]
    overall response rate is defined as the proportion of patients with best overall response (BOR) of complete response (CR) or partial response (PR), as per RECIST 1.1 and blinded independent central review.


Secondary Outcome Measures :
  1. Duration of response [ Time Frame: baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Duration of Response by RECIST 1.1 and as per BIRC

  2. Disease Control [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Disease Control is defined as the proportion of patients with best overall response of CR, PR or SD according to RECIST 1.1 criteria and as per central review

  3. Time to response [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Time to response (TTR) is defined as the time from the date of start of treatment to the first documented response of either complete response (CR) or partial response (PR), which must be subsequently confirmed (although date of initial response is used, not date of confirmation). TTR will be evaluated according to RECIST 1.1

  4. Progression-free survival [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Progression-free survival is defined as the time from the date of first dose to the date of the first documented radiological progression or death due to any cause

  5. Overall survival [ Time Frame: Every 3 months after last visit up to 2 year after last patient first treatment ]
    Overall survival is defined as the time from date of start of treatment to date of death due to any cause

  6. Immune Response Criteria by irRECIST(immune response overall response rate) [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Immune Response Criteria by irRECIST and as per BIRC (immune response objective response rate)

  7. Immune Response Criteria by irRECIST (immune response duration of response) [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Immune Response Criteria by irRECIST and as per BIRC (immune response duration of response)

  8. Immune Response Criteria by irRECIST (immune response time to response) [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Immune Response Criteria by irRECIST and as per BIRC (immune response time to response)

  9. Immune Response Criteria by irRECIST (immune response disease control rate) [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Immune Response Criteria by irRECIST and as per BIRC (immune response disease control rate)

  10. Patient's health-related quality of life [ Time Frame: Baseline, every 8 weeks up to 1 year after last patient first treatment ]
    Global health status/quality of life score of the EORTC QLQ-C30 and the index score of the EQ-5D-5L

  11. Biochemical response [ Time Frame: Baseline, every 28 days until treatment completion (2 yrs max) ]
    Changes from baseline in chromogranin-A and neuron-specific enolase



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically confirmed, advanced (unresectable or metastatic):
  • Well-differentiated (G1 or G2) based on local pathology report, non-functional neuroendocrine tumor of GI, pancreatic or thoracic (including lung and thymus) origin.
  • Poorly-differentiated GEP-NEC based on local pathology report
  • No active symptoms related to carcinoid syndrome during the last 3 months prior to start of study treatment.
  • Patients must have been pretreated for advanced disease - the number of prior systemic therapy/regimen depends on which origin for NET and for GEP-NEC
  • Tumor biopsy material must be provided for all patients for the purpose of biomarker analysis
  • Radiological documentation of disease progression:
  • Well-differentiated NET group: Disease progression while on/or after the last treatment, and this progression must have been observed within 6 months prior to start of study treatment (i.e. maximum of 24 weeks from documentation of progression until study entry). Disease must show evidence of radiological disease progression based on scans performed not more than 12 months apart.
  • Poorly-differentiated GEP-NEC group: Disease progression while on or after prior treatment.

Exclusion Criteria:

  • Well-differentiated grade 3 neuroendocrine tumors; poorly-differentiated neuroendocrine carcinoma of any origin (other than GEP-NEC); including NEC of unknown origin, adenocarcinoid, and goblet cell carcinoid
  • Pretreatment with interferon as last treatment prior to start of study treatment.
  • Prior treatment for study indication with:
  • Antibodies or immunotherapy within 6 weeks before the first dose of study treatment.
  • PRRT administered within 6 months of the first dose.
  • Systemic antineoplastic therapy
  • Tyrosine kinase inhibitors within 14 days or 5 half-lives, whichever is longer, before the first dose of study treatment.
  • Prior PD-1- or PD-L1-directed therapy.
  • Cryoablation, radiofrequency ablation, or trans-arterial embolization of hepatic metastases
  • History of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may pose an increased risk of a serious infusion reaction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02955069


  Show 48 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02955069     History of Changes
Other Study ID Numbers: CPDR001E2201
2016-002522-36 ( EudraCT Number )
First Posted: November 4, 2016    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Advanced or metastatic
NET
pNET
GI NET
thoracic NET
GEP-NEC

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Neuroendocrine Tumors
Carcinoma, Neuroendocrine
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Adenocarcinoma